n(g),n(g')-dimethyl-l-arginine has been researched along with Diabetic Glomerulosclerosis in 23 studies
N,N-dimethylarginine: asymmetric dimethylarginine; do not confuse with N,N'-dimethylarginine
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of the meta-analysis was to evaluate the relationship between serum asymmetric dimethylarginine (ADMA) level and microvascular complications in diabetes mellitus (DM) including diabetic retinopathy (DR), diabetic neuropathy (DN), and diabetic nephropathy." | 9.01 | Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. ( Chen, W; He, K; Li, C; Liu, J; Ma, B; Ma, H; Tian, L; Zhao, P, 2019) |
| "Ramipril was given (5 mg daily for 12 weeks), and circulating ADMA, soluble Fas (sFas), myostatin and endothelial function [flow-mediated vasodilation (FMD); ultrasound)] were measured." | 5.36 | Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? ( Axelsson, J; Caglar, K; Cayci, T; Eyileten, T; Kilic, S; Oguz, Y; Saglam, M; Sonmez, A; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2010) |
| "In patients with T2D, hypertension and overt nephropathy, the renoprotection afforded by telmisartan and valsartan appears similar, and the study was unable to show any effect beyond that due to blood pressure control." | 5.13 | Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. ( Böger, RH; Galle, J; Pinnetti, S; Schwedhelm, E; Wanner, C, 2008) |
| "The purpose of the meta-analysis was to evaluate the relationship between serum asymmetric dimethylarginine (ADMA) level and microvascular complications in diabetes mellitus (DM) including diabetic retinopathy (DR), diabetic neuropathy (DN), and diabetic nephropathy." | 5.01 | Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis. ( Chen, W; He, K; Li, C; Liu, J; Ma, B; Ma, H; Tian, L; Zhao, P, 2019) |
| " Moreover, homocysteine, advanced glycation end products, asymmetric dimethylarginine, and anemia may play a role in the development and progression of atherosclerosis in patients with diabetic nephropathy." | 4.84 | Cardiovascular disease in patients with diabetic nephropathy. ( Aso, Y, 2008) |
| "We aimed to evaluate oxidative stress [8-hydroxydeoxyguanosine (8-OHdG), malondialdehyde (MDA)] endothelial damage [asymmetric dimethylarginine (ADMA)] and markers of cellular inflammation [interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-α), neopterin (NP) and high-sensitivity C-reactive protein (hsCRP)] in patients with diabetic nephropathy (DN) and non-diabetic nephropathy who were being administered hemodialysis treatment because of chronic renal failure." | 3.80 | Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure. ( Agilli, M; Avci, E; Bilgi, C; Cakir, E; Cevher, SC; Yaman, H, 2014) |
| "Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, plays a role in endothelial dysfunction, an initial step of atherosclerosis." | 3.79 | Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction. ( Ando, R; Fukami, K; Kaida, Y; Kaifu, K; Miyazaki, H; Nakayama, Y; Obara, N; Okuda, S; Takeuchi, M; Ueda, S; Yamagishi, S; Yokoro, M, 2013) |
| "Patients with type 2 diabetes and diabetic microvascular complications have significantly elevated levels of Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS)." | 3.01 | Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus. ( Guo, X; Jin, W; Xing, Y, 2023) |
| "This case-cohort study included Chronic Renal Insufficiency Cohort participants with baseline diabetes, estimated glomerular filtration rate <60 mL/min/1." | 1.91 | Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study. ( Anderson, AH; Bhat, Z; Brown, J; Brunengraber, H; Charleston, J; Chen, J; Feldman, HI; He, J; Hostetter, TH; Hsu, CY; Ix, JH; Kimmel, PL; Mehta, R; Rao, P; Sapa, H; Schelling, JR; Schrauben, SJ; Seegmiller, JC; Shafi, T; Shlipak, MG; Townsend, R; Vasan, RS; Xie, D; Zhang, X, 2023) |
| "Endothelial dysfunction, characterized by reduced bioavailability of nitric oxide and increased oxidative stress, is a hallmark characteristic in diabetes and diabetic nephropathy (DN)." | 1.56 | Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy. ( Awad, AS; Cooper, TK; Gao, T; Morris, SM; Stanley, K; Wetzel, MD, 2020) |
| "Albuminuria was calculated using urinary albumin and creatinine ratio (UACR)." | 1.46 | Association of circulatory asymmetric dimethylarginine (ADMA) with diabetic nephropathy in Asian Indians and its causative role in renal cell injury. ( Balasubramanyam, M; Jayachandran, I; Manickam, N; Mohan, V; Paramasivam, P; Subramanian, SC; Sundararajan, S; Venkatesan, B, 2017) |
| "Diabetes and its complications, such as diabetic nephropathy, dramatically increase cardiovascular risk." | 1.46 | ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy. ( Bode-Böger, SM; Brilloff, S; Heinrich, A; Hohenstein, B; Hugo, CPM; Jarzebska, N; Martens-Lobenhoffer, J; Rodionov, RN; Todorov, VT; Weiss, N, 2017) |
| "Seventy patients with type 2 diabetes mellitus and 11 healthy subjects were assessed concerning urine albumin: creatinine ratio, plasma and urinary advanced glycation end-products, plasma asymmetric dimethyl-arginine, serum cystatin C, intima-media thickness in the common carotid arteries, the pulsatility index, the resistance index in the internal carotid arteries and the middle cerebral arteries, the cerebrovascular reactivity through the breath-holding test." | 1.42 | Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study. ( Bob, F; Dumitrascu, V; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Jianu, DC; Petrica, L; Petrica, M; Popescu, R; Ursoniu, S; Velciov, S; Vlad, A; Vlad, D, 2015) |
| "Patients with type 2 diabetes mellitus were divided into three groups according to daily albumin excretion: normoalbuminuria, microalbuminuria and macroalbuminuria (n=30 in each)." | 1.42 | The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes. ( Aycan-Ustyol, E; Bekpinar, S; Dinccag, N; Gurdol, F; Unlucerci, Y; Yenidunya, G, 2015) |
| "A total of 341 type 1 and type 2 diabetes patients with variable degree of kidney disease were included at baseline." | 1.38 | ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis. ( Bartáková, V; Bělobrádková, J; Jurajda, M; Kaňková, K; Klepárník, M; Krusová, D; Kuricová, K; Malúšková, D; Mužík, J; Olšovský, J; Pácal, L; Pavlík, T; Rehořová, J; Stěpánková, S; Svojanovský, J; Tanhäuserová, V; Tomandl, J, 2012) |
| "Ramipril was given (5 mg daily for 12 weeks), and circulating ADMA, soluble Fas (sFas), myostatin and endothelial function [flow-mediated vasodilation (FMD); ultrasound)] were measured." | 1.36 | Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway? ( Axelsson, J; Caglar, K; Cayci, T; Eyileten, T; Kilic, S; Oguz, Y; Saglam, M; Sonmez, A; Vural, A; Yaman, H; Yenicesu, M; Yilmaz, MI, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (34.78) | 29.6817 |
| 2010's | 12 (52.17) | 24.3611 |
| 2020's | 3 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, X | 1 |
| Xing, Y | 1 |
| Jin, W | 1 |
| Schrauben, SJ | 1 |
| Sapa, H | 1 |
| Xie, D | 1 |
| Zhang, X | 1 |
| Anderson, AH | 1 |
| Shlipak, MG | 1 |
| Hsu, CY | 1 |
| Shafi, T | 1 |
| Mehta, R | 1 |
| Bhat, Z | 1 |
| Brown, J | 1 |
| Charleston, J | 1 |
| Chen, J | 1 |
| He, J | 1 |
| Ix, JH | 1 |
| Rao, P | 1 |
| Townsend, R | 1 |
| Kimmel, PL | 1 |
| Vasan, RS | 1 |
| Feldman, HI | 1 |
| Seegmiller, JC | 1 |
| Brunengraber, H | 1 |
| Hostetter, TH | 1 |
| Schelling, JR | 1 |
| Rodionov, RN | 2 |
| Jarzebska, N | 2 |
| Schneider, A | 1 |
| Rexin, A | 1 |
| Sradnick, J | 1 |
| Brilloff, S | 2 |
| Martens-Lobenhoffer, J | 2 |
| Bode-Böger, SM | 2 |
| Todorov, V | 1 |
| Hugo, C | 1 |
| Weiss, N | 2 |
| Hohenstein, B | 2 |
| Wetzel, MD | 1 |
| Gao, T | 1 |
| Stanley, K | 1 |
| Cooper, TK | 1 |
| Morris, SM | 1 |
| Awad, AS | 1 |
| Jayachandran, I | 1 |
| Sundararajan, S | 1 |
| Paramasivam, P | 1 |
| Venkatesan, B | 1 |
| Subramanian, SC | 1 |
| Balasubramanyam, M | 1 |
| Mohan, V | 1 |
| Manickam, N | 1 |
| Heinrich, A | 1 |
| Todorov, VT | 1 |
| Hugo, CPM | 1 |
| Liu, J | 1 |
| Li, C | 1 |
| Chen, W | 1 |
| He, K | 1 |
| Ma, H | 1 |
| Ma, B | 1 |
| Zhao, P | 1 |
| Tian, L | 1 |
| Ando, R | 1 |
| Ueda, S | 2 |
| Yamagishi, S | 3 |
| Miyazaki, H | 1 |
| Kaida, Y | 2 |
| Kaifu, K | 1 |
| Yokoro, M | 1 |
| Nakayama, Y | 1 |
| Obara, N | 1 |
| Fukami, K | 3 |
| Takeuchi, M | 2 |
| Okuda, S | 2 |
| Avci, E | 1 |
| Cakir, E | 1 |
| Cevher, SC | 1 |
| Yaman, H | 2 |
| Agilli, M | 1 |
| Bilgi, C | 1 |
| Petrica, L | 1 |
| Vlad, A | 1 |
| Gluhovschi, G | 1 |
| Gadalean, F | 1 |
| Dumitrascu, V | 1 |
| Vlad, D | 1 |
| Popescu, R | 1 |
| Velciov, S | 1 |
| Gluhovschi, C | 1 |
| Bob, F | 1 |
| Ursoniu, S | 1 |
| Petrica, M | 1 |
| Jianu, DC | 1 |
| Jing, Z | 1 |
| Kuang, L | 1 |
| Liu, N | 1 |
| Yang, J | 1 |
| Bekpinar, S | 1 |
| Yenidunya, G | 1 |
| Gurdol, F | 1 |
| Unlucerci, Y | 1 |
| Aycan-Ustyol, E | 1 |
| Dinccag, N | 1 |
| Aso, Y | 1 |
| Shibata, R | 1 |
| Matsumoto, Y | 1 |
| Hayashida, A | 1 |
| Matsuoka, H | 1 |
| Kato, S | 1 |
| Kimoto, M | 1 |
| Hanai, K | 1 |
| Babazono, T | 1 |
| Nyumura, I | 1 |
| Toya, K | 1 |
| Tanaka, N | 1 |
| Tanaka, M | 1 |
| Ishii, A | 1 |
| Iwamoto, Y | 1 |
| Yilmaz, MI | 1 |
| Sonmez, A | 1 |
| Saglam, M | 1 |
| Cayci, T | 1 |
| Kilic, S | 1 |
| Eyileten, T | 1 |
| Caglar, K | 1 |
| Oguz, Y | 1 |
| Vural, A | 1 |
| Yenicesu, M | 1 |
| Axelsson, J | 1 |
| Tanhäuserová, V | 1 |
| Tomandl, J | 1 |
| Pácal, L | 1 |
| Klepárník, M | 1 |
| Malúšková, D | 1 |
| Bartáková, V | 1 |
| Kuricová, K | 1 |
| Rehořová, J | 1 |
| Stěpánková, S | 1 |
| Svojanovský, J | 1 |
| Olšovský, J | 1 |
| Bělobrádková, J | 1 |
| Krusová, D | 1 |
| Jurajda, M | 1 |
| Mužík, J | 1 |
| Pavlík, T | 1 |
| Kaňková, K | 1 |
| Ojima, A | 1 |
| Ishibashi, Y | 1 |
| Matsui, T | 1 |
| Maeda, S | 1 |
| Nishino, Y | 1 |
| Böger, RH | 2 |
| Schwedhelm, E | 2 |
| Maas, R | 1 |
| Quispe-Bravo, S | 1 |
| Skamira, C | 1 |
| Bellinghieri, G | 1 |
| Santoro, D | 1 |
| Mallamace, A | 1 |
| Di Giorgio, RM | 1 |
| De Luca, G | 1 |
| Savica, V | 1 |
| Chang, JW | 1 |
| Lee, EK | 1 |
| Kim, TH | 1 |
| Min, WK | 1 |
| Chun, S | 1 |
| Lee, KU | 1 |
| Kim, SB | 1 |
| Park, JS | 1 |
| Galle, J | 1 |
| Pinnetti, S | 1 |
| Wanner, C | 1 |
| Schröder, M | 1 |
| Riedel, E | 1 |
| Beck, W | 1 |
| Deppisch, RM | 1 |
| Pommer, W | 1 |
4 reviews available for n(g),n(g')-dimethyl-l-arginine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Role of ADMA in the pathogenesis of microvascular complications in type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Huma | 2023 |
Relationship between Serum Asymmetric Dimethylarginine Level and Microvascular Complications in Diabetes Mellitus: A Meta-Analysis.
Topics: Arginine; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; D | 2019 |
Cardiovascular disease in patients with diabetic nephropathy.
Topics: Anemia; Arginine; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetic Nephr | 2008 |
L-arginine: a new opportunity in the management of clinical derangements in dialysis patients.
Topics: Adult; Aged; Animals; Arginine; Citrulline; Diabetic Nephropathies; Endothelium, Vascular; Female; H | 2006 |
2 trials available for n(g),n(g')-dimethyl-l-arginine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Effects of alpha-lipoic acid on the plasma levels of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
Topics: Adult; Antioxidants; Arginine; Biomarkers; C-Reactive Protein; Cholesterol; Chromatography, High Pre | 2007 |
Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Arginine; Benzimidazoles; Benzoates; Blood Pre | 2008 |
17 other studies available for n(g),n(g')-dimethyl-l-arginine and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Association of urine and plasma ADMA with atherosclerotic risk in DKD cardiovascular disease risk in diabetic kidney disease: findings from the Chronic Renal Insufficiency Cohort (CRIC) study.
Topics: Arginine; Atherosclerosis; Biomarkers; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus; D | 2023 |
ADMA elevation does not exacerbate development of diabetic nephropathy in mice with streptozotocin-induced diabetes mellitus.
Topics: Amidohydrolases; Animals; Arginine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomeru | 2019 |
Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.
Topics: Adenoviridae; Albuminuria; Amidohydrolases; Animals; Arginine; Cytokines; Diabetes Mellitus, Experim | 2020 |
Association of circulatory asymmetric dimethylarginine (ADMA) with diabetic nephropathy in Asian Indians and its causative role in renal cell injury.
Topics: Adult; Albuminuria; Animals; Arginine; Asian People; Biomarkers; Cell Line; Creatinine; Diabetes Mel | 2017 |
ADMA reduction does not protect mice with streptozotocin-induced diabetes mellitus from development of diabetic nephropathy.
Topics: Albuminuria; Amidohydrolases; Animals; Arginine; Cell Proliferation; Creatinine; Diabetes Mellitus, | 2017 |
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction.
Topics: Aged; Amidohydrolases; Arginine; Atherosclerosis; Cells, Cultured; Diabetic Nephropathies; Endotheli | 2013 |
Determination of oxidative stress and cellular inflammation in patients with diabetic nephropathy and non-diabetic nephropathy being administered hemodialysis treatment due to chronic renal failure.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Arginine; Biomarkers; C-Reactive Protein; Case-Control Studies; D | 2014 |
Glycated peptides are associated with the variability of endothelial dysfunction in the cerebral vessels and the kidney in type 2 diabetes mellitus patients: a cross-sectional study.
Topics: Aged; Albuminuria; Arginine; Biomarkers; Breath Holding; Cohort Studies; Cross-Sectional Studies; Di | 2015 |
LC-MS/MS for the simultaneous determination of polar endogenous ADMA and CML in plasma and urine from diabetics.
Topics: Arginine; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Diabetic Nephropathies; H | 2015 |
The effect of nephropathy on plasma sphingosine 1-phosphate concentrations in patients with type 2 diabetes.
Topics: Albuminuria; Apolipoproteins; Apolipoproteins M; Arginine; Biological Transport; Cholesterol, HDL; C | 2015 |
Involvement of asymmetric dimethylarginine (ADMA) in tubulointerstitial ischaemia in the early phase of diabetic nephropathy.
Topics: Adenoviridae; Amidohydrolases; Animals; Arginine; Diabetic Nephropathies; Disease Models, Animal; Ge | 2009 |
Asymmetric dimethylarginine is closely associated with the development and progression of nephropathy in patients with type 2 diabetes.
Topics: Adult; Aged; Albuminuria; Arginine; Biomarkers; Cohort Studies; Cross-Sectional Studies; Diabetes Me | 2009 |
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Arginine; Chronic Disease; Diabetic Nephropat | 2010 |
ADMA, SDMA and L-arginine/ADMA ratio but not DDAH genetic polymorphisms are reliable predictors of diabetic nephropathy progression as identified by competing risk analysis.
Topics: Adult; Aged; Amidohydrolases; Arginine; Cross-Sectional Studies; Czech Republic; Diabetes Mellitus, | 2012 |
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
Topics: Animals; Arginine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Evaluation, Preclin | 2013 |
ADMA and oxidative stress may relate to the progression of renal disease: rationale and design of the VIVALDI study.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ar | 2005 |
Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes.
Topics: Adult; Aged; Arginine; beta 2-Microglobulin; Biocompatible Materials; Blood Pressure; Diabetic Nephr | 2001 |